Amgen has announced plans to invest more than $600 million in a new center for science and innovation at its global headquarters in Thousand Oaks, California. Construction of the facility is expected to begin in the third quarter of 2025. 

The center is designed to bring together researchers, engineers, and scientists across disciplines to enhance collaboration and accelerate the discovery of therapeutics. The building will feature automation and digital capabilities. 

Amgen has invested $40 billion in manufacturing and research and development since 2017, which includes over $5 billion in direct capital expenditures in the US.  

The announcement builds on other recent investments from the company, including a $900-million expansion of its manufacturing facility in Central Ohio and a $1-billion investment to build a second manufacturing plant in Holly Springs, North Carolina. Amgen first announced plans to build the Ohio facility in June 2021, and last year (February 2024), the company opened the nearly 300,000-square-foot final product assembly and packaging plant. The $1-billion expansion in Holly Springs will establish a second drug-substance manufacturing facility. The company broke ground at the facility earlier this year (January 2025). That brought the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550-million commitment there.  

Source: Amgen